Emergent reshuffles its manufacturing brain trust as CEO sends mixed messages around Covid-19 vaccine debacle
Weeks after Maryland-based Emergent BioSolutions bungled 15 million doses of J&J’s Covid-19 shot and was shut out of its own Baltimore facility, the CDMO is set on shaking up its manufacturing leadership. Staring at a big financial hit from the ordeal, though, Emergent still can’t get its story straight on exactly what went down with J&J’s shots.
In an earnings call with investors Thursday, CEO Bob Kramer said a “cross-contamination” mix-up of the adenovirus vectors used in the J&J and AstraZeneca shots produced on site was to blame for the J&J shots being thrown out. But that’s not the story he gave the public earlier this month. In an interview with CNBC on April 1, Kramer said an ingredients mix-up wasn’t the issue but rather that J&J’s shot batch was simply manufactured out-of-spec — which has very different implications in terms of the company’s ability to do its job well.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.